Clinical Trial Detail

NCT ID NCT03565406
Title A Phase 1b Study of the Selective HDAC Inhibitor Mocetinostat in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements No
Sponsors New York University School of Medicine
Indications

melanoma

Therapies

Ipilimumab + Mocetinostat + Nivolumab

Age Groups: adult senior

No variant requirements are available.